Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bristol-Myers Squibb Co Receives Positive Decision From National Institute Of Health And Clinical Excellence (NICE) For YERVOY


Thursday, 1 Nov 2012 08:01pm EDT 

Bristol-Myers Squibb Co announced that the National Institute of Health and Clinical Excellence (NICE)has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD). Metastatic melanoma is the deadliest form of skin cancer with an average life expectancy of just six to nine months and a one-year mortality rate of 75%. YERVOY is the only approved treatment for metastatic melanoma to deliver a durable long-term survival benefit at two years for 24% of patients. In the pivotal study, which included more than 4.5 years of follow up, median overall survival was 10 months (95% CI: 8.0-13.8) for YERVOY and six months (95% CI: 5.5-8.7) for the gp100 control arm. 

Company Quote

51.84
-0.11 -0.21%
22 Oct 2014